More drama ahead: Sarepta plans to file for accelerated Duchenne approval, with adcomm a 'near certainty' – Endpoints News
Business News
- More drama ahead: Sarepta plans to file for accelerated Duchenne approval, with adcomm a ‘near certainty’ Endpoints News
- Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy Yahoo Finance
- Why Sarepta Therapeutics Stock Is Perking Up Today The Motley Fool
- Sarepta to seek an early swift review for Duchenne gene therapy FierceBiotech
- View Full Coverage on Google News
Source: Business News